# Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

> **NCT01273155** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 72 (actual)

## Conditions studied

- Neoplasms
- Lymphomas

## Interventions

- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT01273155
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-10
- **Primary completion:** 2017-10-25
- **Final completion:** 2017-10-25
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273155, "Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01273155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*